日
関

WordNet

a complex consisting of an organic base in association with hydrogen chloride

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2012/12/15 10:16:14」(JST)

wiki en

Trimethobenzamide (Tebamide, Tigan) is an antiemetic used to prevent nausea and vomiting. It is often prescribed for patients with gastroenteritis, medication-induced nausea, and other illnesses. Trimethobenzamide is generally considered the most potent antiemetic that does not have effects on the serotonergic, dopaminergic, or histaminergic systems, so it has a lower likelihood of causing undesired side effects. In the United States, it requires a prescription.

Mechanism of action

Although the specific mechanism through which trimethobenzamide functions is unknown, it is believed to affect the chemoreceptor trigger zone (CTZ) of the medulla oblongata.

Side effects

Possible side effects include drowsiness, dizziness, headache, diarrhea, muscle cramps, and blurred vision. More serious adverse effects include skin rash, tremors, parkinsonism, and jaundice.

Formulations

Trimethobenzamide is marketed under the brand names Tebamide and Tigan, manufactured by GlaxoSmithKline and King Pharmaceuticals, respectively. It is available as oral capsules and injectable formulations.

Trimethobenzamide was also available as a rectal suppository, but such formulations were banned by the U.S. Food and Drug Administration on April 6, 2007 due to unproven efficacy.^[1]

References

^ Waknine, Yael (April 6, 2007). "FDA Bans Suppositories With Trimethobenzamide". Medscape. Archived from the original on April 16, 2007. http://web.archive.org/web/20070416054940/http://www.medscape.com/viewarticle/554812. Retrieved 2007-04-06.

External links

Tebamide (manufacturer's website)^{[dead link]}
Tigan (manufacturer's website)^{[dead link]}

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 制吐剤の特性 characteristics of antiemetic drugs
2. パーキンソン病の薬理学的治療 pharmacologic treatment of parkinson disease
3. パーキンソン病における症状の変動およびジスキネジア motor fluctuations and dyskinesia in parkinson disease
4. 経口補水療法 oral rehydration therapy

English Journal

Clinical and economic outcomes associated with potentially inappropriate prescribing in the elderly.

Stockl KM1, Le L, Zhang S, Harada AS.
The American journal of managed care.Am J Manag Care.2010 Jan 1;16(1):e1-10.
OBJECTIVE: To evaluate the risk of adverse events (AEs) and the healthcare costs for elderly patients receiving specific potentially inappropriate medications (PIMs).STUDY DESIGN: Retrospective cohort study.METHODS: Patients 65 years and older who started 1 of 23 PIMs were matched with control subje
PMID 20059286

Effects of antiemetic drugs on glucose 6-phosphate dehydrogenase and some antioxidant enzymes.

Ozmen I1, Küfrevioglu OI.
Pharmacological research : the official journal of the Italian Pharmacological Society.Pharmacol Res.2004 Nov;50(5):499-504.
The aim of this study was to investigate effect of antiemetics on G6PD and antioxidant enzymes. Antiemetics are currently being used to reduce or prevent nausea and vomiting in patients. This is the first study to show effect of antiemetics on glucose-6-phosphate dehydrogenase (G6PD) and antioxidant
PMID 15458770

Spectrophotometric determination of some pharmaceutical amides through charge-transfer complexation reactions.

Saleh GA1, Askal HF.
Journal of pharmaceutical and biomedical analysis.J Pharm Biomed Anal.1991;9(3):219-24.
A spectrophotometric method is described for the assay of fenpipramide hydrochloride, isopropamide iodide, trimethobenzamide hydrochloride, morphazinamide hydrochloride and tolazamide. The method is based on the formation of a charge-transfer complex between the drug as n-donor and iodine, a sigma-a
PMID 1678622

Related Pictures

Trimethobenzamide Hydrochloride pill identification by imprinted code,color and shape DailyMed - TRIMETHOBENZAMIDE HYDROCHLORIDE- trimethobenzamide hydrochloride capsule Tigan - FDA prescribing information, side effects and uses Pillbox - National Library of Medicine

★リンクテーブル★

リンク元	「トリメトベンズアミド」「塩酸トリメトベンズアミド」
関連記事	「trimethobenzamide」「hydrochloride」

「トリメトベンズアミド」

Trimethobenzamide
Systematic (IUPAC) name
	N-{[4-(2-dimethylaminoethoxy)phenyl]methyl}-; 3,4,5-trimethoxy-benzamide
Clinical data
Trade names	Tigan
AHFS/Drugs.com	monograph
MedlinePlus	a682693
Pregnancy cat.	?
Legal status	℞-only (US)
Routes	Oral, rectal, intramuscular
Pharmacokinetic data
Half-life	7 to 9 hours (mean)
Identifiers
CAS number	138-56-7
ATC code	None
PubChem	CID 5577
DrugBank	DB00662
ChemSpider	5375
UNII	W2X096QY97
ChEBI	CHEBI:27796
ChEMBL	CHEMBL1201256
Chemical data
Formula	C21H28N2O5
Mol. mass	388.458 g/mol
	SMILES O=C(c1cc(OC)c(OC)c(OC)c1)NCc2ccc(OCCN(C)C)cc2;
	InChI InChI=1S/C21H28N2O5/c1-23(2)10-11-28-17-8-6-15(7-9-17)14-22-21(24)16-12-18(25-3)20(27-5)19(13-16)26-4/h6-9,12-13H,10-11,14H2,1-5H3,(H,22,24) ; Key:FEZBIKUBAYAZIU-UHFFFAOYSA-N ;
(what is this?) (verify);